Drugs / GBP510
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT04750343 | Feb → Jul 2021 | — | SK Bioscience Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT04742738 | Jan → Jul 2021 | — | SK Bioscience Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05175950 | Jan 2022 → Aug 2023 | — | Korea University Guro Hospital | Unknown | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT05501522 | Dec 2022 → Aug 2023 | COVID-19 | SK Bioscience Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT05007951 | Aug 2021 → Oct 2023 | COVID-19 | SK Bioscience Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GBP510 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04750343 ↗ |
| Modality | Vaccine | “SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510)” NCT04742738 ↗ |
| Route | Intramuscular | “Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with Alum (RBD 10μg/dose) on Days 0 and 28.” NCT04742738 ↗ |